Robertson Stephens Wealth Management LLC Buys 1,211 Shares of Johnson & Johnson (NYSE:JNJ)

Robertson Stephens Wealth Management LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,286 shares of the company’s stock after buying an additional 1,211 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Massachusetts Wealth Management increased its stake in shares of Johnson & Johnson by 4.2% in the 3rd quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock worth $2,508,000 after purchasing an additional 650 shares in the last quarter. Ridgewood Investments LLC grew its holdings in Johnson & Johnson by 50.9% during the third quarter. Ridgewood Investments LLC now owns 5,861 shares of the company’s stock valued at $913,000 after purchasing an additional 1,976 shares during the period. Brookstone Capital Management increased its position in Johnson & Johnson by 20.4% in the third quarter. Brookstone Capital Management now owns 68,596 shares of the company’s stock worth $10,449,000 after buying an additional 11,643 shares in the last quarter. Kathleen S. Wright Associates Inc. lifted its position in shares of Johnson & Johnson by 210.0% during the 3rd quarter. Kathleen S. Wright Associates Inc. now owns 9,300 shares of the company’s stock valued at $1,457,000 after buying an additional 6,300 shares in the last quarter. Finally, FAS Wealth Partners Inc. grew its stake in shares of Johnson & Johnson by 1.7% during the 3rd quarter. FAS Wealth Partners Inc. now owns 33,017 shares of the company’s stock valued at $5,142,000 after acquiring an additional 546 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on JNJ. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada lowered their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $175.86.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $148.57 on Tuesday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The firm’s fifty day moving average is $153.95 and its 200 day moving average is $155.00. The company has a market cap of $357.56 billion, a price-to-earnings ratio of 9.26, a PEG ratio of 2.46 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.68 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.34%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 29.68%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.